Compugen Valuation
Is CGEN undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of CGEN when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate CGEN's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate CGEN's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for CGEN?
Key metric: As CGEN is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is CGEN's PE Ratio? | |
|---|---|
| PE Ratio | 81.2x |
| Earnings | US$1.60m |
| Market Cap | US$128.04m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 0.3x |
| Enterprise Value/EBITDA | 1.7x |
| PEG Ratio | -1.4x |
Price to Earnings Ratio vs Peers
How does CGEN's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 46x | ||
KMDA Kamada | 21.6x | 16.1% | ₪1.3b |
GFC-M G.F.C Green Fields Capital | 5.4x | n/a | ₪115.4m |
1875 TOT BIOPHARM International | 151.7x | n/a | HK$1.5b |
2142 HBM Holdings | 5.4x | n/a | HK$894.2m |
CGEN Compugen | 81.2x | -59.8% | ₪128.0m |
Price-To-Earnings vs Peers: CGEN is expensive based on its Price-To-Earnings Ratio (81.2x) compared to the peer average (46.1x).
Price to Earnings Ratio vs Industry
How does CGEN's PE Ratio compare vs other companies in the Asian Biotechs Industry?
| 1 Company | Price / Earnings | Estimated Growth | Market Cap |
|---|---|---|---|
| 1 Company | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Earnings vs Industry: CGEN is expensive based on its Price-To-Earnings Ratio (81.2x) compared to the Asian Biotechs industry average (33x).
Price to Earnings Ratio vs Fair Ratio
What is CGEN's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 81.2x |
| Fair PE Ratio | n/a |
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate CGEN's Price-To-Earnings Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Evogene
₪32.5m
Operates as a computational biology company.
EVGN
₪6.07
7D
-10.8%
1Y
-72.3%
Protalix BioTherapeutics
US$112.5m
A biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally.
PLX
US$7.33
7D
-0.1%
1Y
97.5%